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Abstract 
Background: The role of omega‑3 polyunsaturated fatty acids (n‑3PUFA), and the potential impact of n‑3PUFA sup‑
plementation, in the treatment and management of type 1 diabetes (T1D) remains unclear and controversial. There‑
fore, this study aimed to examine the efficacy of daily high‑dose‑bolus n‑3PUFA supplementation on vascular health, 
glycaemic control, and metabolic parameters in subjects with T1D.
Methods: Twenty‑seven adults with T1D were recruited to a 6‑month randomised, double‑blind, placebo‑controlled 
trial. Subjects received either 3.3 g/day of encapsulated n‑3PUFA or encapsulated 3.0 g/day corn oil placebo (PLA) for 
6‑months, with follow‑up at 9‑months after 3‑month washout. Erythrocyte fatty acid composition was determined 
via gas chromatography. Endpoints included inflammation‑associated endothelial biomarkers (vascular cell adhe‑
sion molecule‑1 [VCAM‑1], intercellular adhesion molecule‑1 [ICAM‑1], E‑selectin, P‑selectin, pentraxin‑3, vascular 
endothelial growth factor [VEGF]), and their mediator tumor necrosis factor alpha [TNFα] analysed via immunoassay, 
vascular structure (carotid intima‑media thickness [CIMT]) and function (brachial artery flow mediated dilation [FMD]) 
determined via ultrasound technique, blood pressure, glycosylated haemoglobin (HbA1c), fasting plasma glucose 
(FPG), and postprandial metabolism.
Results: Twenty subjects completed the trial in full. In the n‑3PUFA group, the mean ± SD baseline n‑3PUFA index of 
4.93 ± 0.94% increased to 7.67 ± 1.86% (P < 0.001) after 3‑months, and 8.29 ± 1.45% (P < 0.001) after 6‑months. Total 
exposure to n‑3PUFA over the 6‑months (area under the curve) was 14.27 ± 3.05% per month under n‑3PUFA, and 
9.11 ± 2.74% per month under PLA (P < 0.001). VCAM‑1, ICAM‑1, E‑selectin, P‑selectin, pentraxin‑3, VEGF, TNFα, CIMT, 
FMD, blood pressure, HbA1c, FPG, and postprandial metabolism did not differ between or within groups after treat‑
ment (P > 0.05).
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Background
The role of omega-3 polyunsaturated fatty acids 
(n-3PUFA), and the potential impact of n-3PUFA supple-
mentation, in the treatment and management of diabetes 
remains unclear and controversial. Cross-sectional epi-
demiological studies suggest that inadequate n-3PUFA 
intake is associated with an increased risk of developing 
both type 2 diabetes (T2D) [1] and type 1 diabetes (T1D) 
[2]. However, a recent meta-analysis of randomised con-
trolled trials (RCTs) concluded that n-3PUFA supple-
mentation has little effect on the prevention of T2D in 
humans [3], and evidence for preventing T1D remains 
preliminary and limited to animal studies [4]. In murine 
models, research has shown that increased n-3PUFA 
intake reduces the risk of microvascular complications 
in vivo [5], and some studies [6, 7], although not all [8], 
have shown n-3PUFA supplementation improves bio-
markers of vascular health and metabolic parameters in 
people with T2D [9, 10]. However, RCTs investigating 
n-3PUFA supplementation in T2D have failed to show 
reductions in major vascular events [11].
Dietary recommendations for people with and without 
diabetes currently advocate increased consumption of 
foods rich in n-3PUFA but do not recommend n-3PUFA 
supplementation [12]. However, the evidence underpin-
ning these recommendations for people with diabetes is 
limited exclusively to people with T2D as very few RCTs 
have examined the impact of n-3PUFA supplementation 
on vascular or metabolic outcomes in T1D [13–18]. Fur-
ther, most RCTs in T1D are confounded by short dura-
tion supplementation, low n-3PUFA dose, and failure to 
control for pretreatment fatty acid profile status. There-
fore, the objective of this study was to investigate the effi-
cacy of high-dose-bolus n-3PUFA supplementation on 
vascular health, glycaemic control, and metabolic param-
eters in adults with T1D.
Methods
We performed a single-centre, parallel-group, double-
blind, randomised, placebo-controlled trial in subjects 
with T1D, testing the efficacy of 6-months high-dose-
bolus n-3PUFA supplementation on vascular health, 
glycaemic control, and metabolic parameters. Outcome 
assessments and safety outcomes were recorded at 
baseline, and after 3- and 6-months, with further assess-
ment at 9-months following a subsequent 3-month wash-
out (Additional file 1: Fig. S1). This trial was prospectively 
registered at the International Clinical Trials Registry 
Platform (ID: ISRCTN40811115), and ethical approval 
was granted by the local National Health Service 
Research Ethics Committee (17/NE/0244). In June 2018 
a substantial ethics amendment was approved to increase 
the pool of available study participants. The amendment 
served to modify the inclusion criteria from “Not taking 
any prescribed medication other than insulin” to “Not 
taking any medication known to interact with n-3PUFA 
supplementation”. All subjects provided written informed 
consent before participating in the trial. Recruitment 
took place from September 2017–January 2019.
Twenty-seven adults aged 18–65  years with a diagno-
sis of T1D (glycosylated haemoglobin [HbA1c]: < 11% 
[97  mmol/mol]) > 2  years on enrolment and free from 
diabetes-related complications were eligible for inclu-
sion. Exclusion criteria included any significant medical 
conditions including hepatic or haematological abnor-
malities, compromised glycaemic control (HbA1c > 11% 
(97  mmol/mol), current or previous pregnancy within 
the last 12-months or planning to become pregnant 
within 12-months, and taking any medication known to 
interact with n-3PUFA. All subjects were treated with a 
stable basal-bolus insulin regimen using either continu-
ous subcutaneous  insulin infusion (n = 9) or multiple 
daily injection (n = 11) therapy. Subjects following con-
tinuous subcutaneous insulin infusion therapy used insu-
lins Aspart (n = 6) or Lispro (n = 3). For multiple daily 
injection therapy the basal component consisted of insu-
lins Glargine (n = 5), Degludec (n = 2), Detemir (n = 3), 
or Isophane (n = 1) and the bolus component consisted 
of rapid-acting insulins Aspart (n = 8), Lispro (n = 2), 
or Glulisine (n = 1). Subjects were required to maintain 
their usual dietary habits and existing use of multivita-
mins throughout the duration of the study.
Following study enrolment, subjects were randomly 
assigned to treatment with n-3PUFA or placebo (PLA) 
in a 1:1 allocation ratio. Randomisation was conducted 
via the Minimization Program for allocating patients 
to clinical trials [19]; this algorithm ensures a balanced 
allocation of subjects across both groups for prognostic 
Conclusions: This study indicates that daily high‑dose‑bolus of n‑3PUFA supplementation for 6‑months does not 
improve vascular health, glucose homeostasis, or metabolic parameters in subjects with T1D. The findings from this 
preliminary RCT do not support the use of therapeutic n‑3PUFA supplementation in the treatment and management 
of T1D and its associated complications.
Trial Registration ISRCTN, ISRCTN40811115. Registered 27 June 2017, http://www.isrct n.com/ISRCT N4081 1115.
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factors (i.e. age, BMI, diabetes duration). Randomi-
zation and safety monitoring as well as study drug 
labelling and dispensing were completed by staff not 
involved in recruitment or testing procedures. All sub-
jects, clinical investigators, and outcome assessors were 
blinded to treatment allocation.
Subjects randomised to n-3PUFA supplementation 
ingested a daily high-dose-bolus of encapsulated 3.3 g/
day (2.3  g EPA and 0.8  g DHA) (OmegaVia fish oil, 
OmegaVia, Calabasas, USA) over a 6-month period, 
whereas the placebo group ingested an encapsulated 
dose of 3.0  g/day corn oil (Pure corn oil, Mazola, Liv-
erpool, UK). Capsules were aesthetically identical and 
dispensed in sealed pharmaceutical bottles. Monthly 
emails were sent individually to ensure compliance and 
monitor adverse effects. Subjects were instructed to 
retain packaging and informed that compliance would 
be objectively assessed through periodic blood analysis. 
On each laboratory visit, upper gastrointestinal symp-
toms (reflux, abdominal pain, and indigestion) were 
assessed via a self-administered validated questionnaire 
[20].
Subjects attended four separate but identical morning-
time laboratory visits at baseline, 3-months, 6-months, 
and 9-months. Subjects refrained from caffeine, alcohol, 
and vigorous physical activity in the 48-h prior to each 
laboratory visit, in addition to adopting an overnight fast. 
During each visit, resting blood samples were obtained 
to analyse vascular and metabolic biomarkers. Vascu-
lar structure and function were assessed via ultrasound. 
Anthropometric measures (weight, body mass index, 
percentage body fat) were obtained via bioelectrical 
impedance analysis (SC-331S, Tanita, Amsterdam, Neth-
erlands), and blood pressure was assessed via an auto-
mated oscillometric device (Intellisense HEM-907XL, 
Omron, Kyoto, Japan). In addition, subjects completed 
two subsequent mixed-meal tolerance tests to assess the 
potential impact of n-3PUFA supplementation on post-
prandial metabolism (see Additional file  1: Fig.  S1 and 
Table S1).
On arrival to the laboratory, a 22-gauge cannula (Vaso-
fix, B.Braun, Melsungen AG, Germany) was inserted into 
the antecubital vein of the non-dominant arm which 
was kept patent for periodic blood draws. Following ini-
tial measures (anthropometry and vascular assessment), 
subjects completed a meal-tolerance test (see Additional 
file  1: Table  S1). At 4-h post-breakfast, subjects com-
pleted a second meal-tolerance test (see Additional file 1: 
Table S1) followed by a 4-h observation window. Subjects 
were instructed to consume each meal within a 20-min 
window and were permitted water intake ad libitum, for 
which quantity was recorded. Blood draws were made 
throughout the meal tolerance tests at 30-min intervals.
Venous blood samples were collected using 3  mL 
EDTA vacutainers and 6 mL lithium-heparin vacutain-
ers (BD, New Jersey, USA). Fasting whole blood samples 
from each visit were analysed for HbA1c and erythro-
cyte fatty acid composition (Omegametrix GmbH labo-
ratory, Planegg, Germany) via gas chromatography by 
methods described previously [21]; erythrocyte fatty 
acid composition was determined to establish baseline 
fatty acid status and was used as an objective meas-
ure of compliance to the intervention. The n-3PUFA 
index (O3I) was calculated as eicosapentaenoic acid 
plus docosahexaenoic acid. The remaining blood sam-
ple was centrifuged at 2700×g for  10  min  at  4  °C and 
the resultant plasma was subsequently stored at − 80 °C 
for retrospective analysis of vascular biomarkers and 
metabolic parameters. A customised 7-plex human 
fluid-phase magnetic immunoassay (R&D Systems, 
Minneapolis, USA) was used for the simultaneous 
detection and quantification of vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion mol-
ecule-1 (ICAM-1), E-selectin, P-selectin, pentraxin-3, 
vascular endothelial growth factor (VEGF), and tumor 
necrosis factor alpha (TNFα) as per the manufacturer’s 
instructions. All vascular biomarker data were collected 
on a  Luminex® 200™ cytometer (Luminex, Texas, USA) 
and analysed using specialised software (Bio-Plex Man-
ager 6.1, Bio-Rad, California, USA). In addition, fasting 
plasma glucose (FPG), triglycerides, cholesterol, and 
non-esterified fatty acids (NEFA) were quantified via an 
enzymatic  colorimetric  assay using a fully automated 
random-access analyser (Randox Daytona Plus, Randox 
Laboratories, UK). Further blood draws were made at 
30-min intervals for the duration of the 8-h laboratory 
stay to capture postprandial glucose (PPGR) and tri-
glyceride (PPTR) responses to each meal tolerance test; 
the trapezoidal rule was used to calculate individual 
areas under the plasma concentration curves (AUC); 
data is presented as sum AUC (0–8 h) for two consecu-
tive mixed-meal tolerance tests. The intra-assay coeffi-
cient of variation was < 5% for all biochemical analyses.
Non-invasive high-resolution B-mode ultrasound 
imaging (GE Healthcare, Vivid I BT 12 EMEA, Illinois, 
USA) was performed using a GE 9L linear array ultra-
sound transducer probe (GE Healthcare, 12L-RS Linear 
Probe, Illinois, USA), to assess carotid-artery intima-
media thickness (CIMT) and brachial artery flow medi-
ated dilation (FMD) via previously described methods 
[22, 23]. Independently validated edge detection soft-
ware (Vascular Research Tools 6, Medical Imaging 
Application, LLC, Iowa, USA) was used for offline anal-
ysis of all ultrasound images.
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Sample size and statistical analysis
Sample size for this study was estimated on the basis 
of prior work in T1D with shared similarities as well as 
published meal tolerance data [24–26]. Priori power 
calculations estimated a sample size of n = 16 in each 
arm would provide 80% power with α set at 0.05 to 
detect a small effect (d = 0.25) in the change variables 
for primary and secondary outcomes, namely: VCAM-
1, E selectin, P-selectin, TNFα, pentraxin-3, ICAM-1, 
VEGF, HbA1c, triglycerides, PPGR, and PPGT [27]. On 
completion of the study, we used the realised sample 
size (20 subjects rather than 32) and standard error to 
calculate post hoc power for the observed estimates. 
Post-hoc power analysis on the attained sample size 
calculated the estimated power to be: > 99% for VCAM-
1, E selectin, P-selectin, TNFα, pentraxin-3, FMD, 
CIMT, HbA1c, and triglycerides; 98% and 94% for 
PPTR and PPGR, respectively; 89% for ICAM-1; and 
64% for VEGF.
Statistical analysis was performed using SPSS (Version 
26, IBM, Illinois, USA). Primary analysis was per proto-
col and performed using a general linear mixed model 
repeated-measures analysis of variance. Secondary analy-
sis was performed as intention to treat with last observa-
tion carried forward. The within-groups factor was time 
with treatment allocation as the between-groups factor. 
Pairwise comparisons were used to investigate signifi-
cant interactions adjusted using a Bonferroni correction. 
Statistical models were further adjusted to include pre-
treatment fatty-acid exposure, and age, gender, age of 
diagnosis, duration of disease, and mode of insulin ther-
apy as prognostic markers. Total exposure to n-3PUFA 
during the study period was calculated as the individual 
areas under the plasma concentration curves derived 
from the measurements at baseline and after 3-months, 
6-months, and 9-months by using the trapezoidal rule. 
Statistical significance was set at P ≤ 0.05. Data are pre-
sented mean ± SD.
Results
Study recruitment and follow‑up
We screened 218 subjects randomly allocating a total of 
27 to treatment with n-3PUFA (n = 14) or PLA (n = 13) 
(Fig.  1). The main exclusion criteria were either sig-
nificant medical conditions (42%) or pre-existing self-
administration of n-3PUFA supplementation (25%). One 
subject was removed from the study shortly following 
baseline laboratory analysis due to elevated pretreatment 
HbA1c. Six subjects were lost to follow-up, and therefore 
20 subjects completed the study in full (n-3PUFA, n = 10; 
PLA, n = 10). Subject demographic and pretreatment 
clinical characteristics are shown in Table 1.
Outcomes
No significant differences were found between n-3PUFA 
and PLA groups in vascular, glycaemic, or metabolic end-
points (Table 2). The change in inflammatory-associated 
vascular endothelial proteins (VCAM-1, ICAM-1, VEGF, 
E-selectin, P-selectin, pentraxin-3) and TNFα measured 
as the difference between baseline and 6-months showed 
no significant differences between n-3PUFA and PLA 
(Table  2). Similarly, CIMT and FMD, as well as blood 
pressure remained unchanged in both n-3PUFA and PLA 
groups (P > 0.05; Table 2). The change in glycaemic con-
trol, measured as HbA1c, FPG, and PPGR, did not differ 
between groups; no within-group changes during treat-
ment were found (P > 0.05; Table 2). Fasting cholesterol, 
NEFA, and triglyceride levels, as well as PPTR, remained 
unchanged and were not different within or between 
groups (P > 0.05; Table  2). Likewise, body weight, body 
mass index, and percentage body fat remained similar 
between the two treatment groups throughout the study 
(P > 0.05; Table  2). No changes in insulin requirements 
were observed with basal and bolus insulin doses remain-
ing unchanged within each group. Bolus insulin admin-
istration was maintained for all mixed-meal tolerance 
tests across all four visits (n-3PUFA: 9.27 ± 3.00 IU; PLA: 
8.04 ± 4.19 IU).
Erythrocyte fatty acid composition
In the n-3PUFA group, baseline O3I of 4.93 ± 0.94% 
increased to 7.67 ± 1.86% (P < 0.001) after 3-months, and 
8.29 ± 1.45% (P < 0.001) after 6-months, before decreas-
ing to 5.84 ± 0.22% (P = 0.005) at 9-months following 
washout. Total exposure to n-3PUFA over the 6-months 
(area under the curve) was 14.27 ± 3.05% per month and 
9.11 ± 2.74% per month in the n-3PUFA and PLA groups, 
respectively (P < 0.001). Comprehensive erythrocyte fatty 
acid profiles for saturated, monounsaturated, and poly-
unsaturated fatty acids across both groups at all time 
points are presented in Additional file 1: Table S2.
Adjustment for pretreatment fatty acid composition, 
age, gender, age of T1D diagnosis, duration of diabetes, 
or mode of insulin therapy did not impact outcomes 
(Additional file  1: Table  S3). Intention-to-treat analyses 
on the basis of last observation carried forward did not 
significantly alter outcomes (Additional file 1: Table S5).
Safety
Overall, no important safety issues occurred during 
n-3PUFA supplementation. The mean severity of gastro-
intestinal side effects assessed did not significantly differ 
over time for either treatment condition. The reported 
severity of gastrointestinal symptoms changed from no 
symptoms to mild during the 6-month supplementation 
period in seven subjects (n-3PUFA: n = 2; PLA: n = 5), 
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whereas symptoms changed from mild to moderate in 
five subjects (n-3PUFA: n = 3; PLA: n = 2).
Discussion
In this RCT of n-3PUFA versus placebo in subjects with 
T1D, daily high-dose-bolus n-3PUFA supplementation 
for 6-months did not improve vascular health, glycae-
mic control, or metabolic parameters in subjects with 
T1D. These findings have important clinical implications 
concerning dietary recommendations and nutritional 
guidance for people with T1D. Specifically, our findings 
question the efficacy of n-3PUFA supplementation for 
the treatment and management of T1D and its associated 
complications. Our data support previous studies con-
ducted in T2D patients [28–32] and provide new insight 
within the context of T1D [13–18].
This is the first study to comprehensively assess the 
impact of n-3PUFA supplementation on vascular health 
in subjects with T1D. We have previously shown that 
inflammation and vascular markers are raised in people 
with T1D, even in those with good metabolic control 
[26, 33]. The pretreatment inflammatory cytokine and 
endothelial cell adhesion molecule concentrations of 
patients in the present study, appear elevated compared 
to previously published data in T1D [26, 34]. Such differ-
ences may be due to differences in clinical characteristics 
(i.e. age, BMI, and diabetes duration) between study pop-
ulations and indicates increased endothelial activation 
our patients. It is widely recognised that vascular adhe-
sion molecules play an important pathophysiological role 
in atherosclerosis [35], and are upregulated early into the 
progression of microvascular complications in subjects 
with T1D [36]. n-3PUFAs have previous been shown to 
attenuate the expression of adhesion molecules and vas-
cular inflammation in human endothelial cells in  vitro 
[9, 10, 37]. Additionally, the metabolism of n-3PUFA: 
(i) modulates macrophage functions [38], (ii) produces 
bioactive metabolites which possess anti-inflammatory 
Fig. 1 Subject enrolment, random assignment, and follow up reported in accordance with Consolidated Standards of Reporting Trials guidelines
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properties [39], and (iii) reduces atherogenesis and 
platelet aggregation [40]. A high n-6PUFA:n-3PUFA 
ratio has also been associated with increased systemic 
inflammation in T2D [41]. Therefore, it is plausible to 
speculate that similar improvements in vascular inflam-
mation would be observed in people with T1D following 
n-3PUFA supplementation. Notably, however, no signifi-
cant improvements were detected in vascular adhesion 
molecules or their mediator TNFα in the present study. 
In addition, we found no effect of n-3PUFA supple-
mentation on CIMT, FMD, or blood pressure. Previous 
research investigating n-3PUFA supplementation in T2D 
has reported conflicting results regarding CIMT [32, 42] 
and blood pressure responses [6, 43].
Further, we report for the first time, the impact of 
n-3PUFA supplementation on postprandial metabo-
lism. Postprandial metabolic handling is a strong and 
independent predictor of cardiovascular disease [44, 45] 
and a critical component of T1D self-management. We 
show that a daily high-dose-bolus of n-3PUFAs does 
not modulate postprandial glycemia or lipemia. Addi-
tionally, it was found n-3PUFA supplementation does 
not improve long-term glycaemic control or metabolic 
parameters. Prior research investigating the utility of 
n-3PUFAs in T1D has shown both improvements [18] 
and no change on glucose homeostasis [13, 14, 17]. The 
beneficial effects of n-3PUFAs on fasting triglycerides are 
well documented in T2D [46]. Although not statistically 
significant, we observed a numerical reduction in fasting 
triglyceride levels in the n-3PUFA arm at 3-months and 
6-months that was restored following washout. In our 
study, changes in fasting triglycerides from 3 to 9 months 
in the PLA group may have masked a statistically signifi-
cant effect in the n-3PUFA group. Although speculative, 
one potential mechanism for triglyceride reduction is 
decreased secretion of inflammatory cytokines, which 
reduces hepatic very low-density lipoprotein synthesis 
and accelerates chylomicron clearance [47, 48]. Consid-
ering our chosen inflammatory biomarkers, particularly 
TNFα, remained unchanged, this could, in part, explain 
why triglyceride levels in our participants remained 
statistically unchanged. Although, reductions in fast-
ing triglyceride levels have been shown in response to 
n-3PUFAs independent of baseline triglyceride values, 
higher reductions in triglycerides are observed when 
baseline triglycerides are elevated [49–51]. Further, the 
Table 1 Pretreatment demographic and clinical characteristics of study subjects included in final analysis
Data presented as mean ± SD. n-3PUFA compared to placebo. Independent samples t tests were performed on metric variables a; Fisher exact tests performed on 
categorical variables b. n-3PUFA, omega-3 polyunsaturated fatty acid. Omega-3 index calculated as eicosapentaenoic acid plus docosahexaenoic acid. A, Aspart; D, 
Detemir; DG, Degludec; G, Glargine; GL, Glulisine; I, Isophane; L, Lispro
n‑3PUFA Placebo P value
Total n 10 10 –
Gender 0.582b
 Male 9 7 –
 Female 1 3 –
Insulin therapy (n) 0.370b
 Multiple daily injection 7 4 –
Basal insulin 4G;  2D;  1DG 1D;  1DG;  1G;  1I
Bolus insulin 5A;  2L 3A;  1GL
 Continuous subcutaneous insulin infusion 3A 3A;  3L –
Total daily insulin dose (IU) 41.3 ± 7.7 40.1 ± 9.5 0.776a
Medication 1 Atorvastatin 1 Lisinopril 1 Atorvastatin, Metformin, and Nefo‑
pam
1 Levothyroxine
1 Lisinopril and Pravastatin
1.000b
Age (y) 32 ± 12 36 ± 17 0.524a
Body mass index (kg/m2) 25.13 ± 3.43 28.14 ± 6.38 0.205a
Duration of diabetes (y) 15 ± 13 21 ± 12 0.284a
Age of diagnosis (y) 17 ± 8 16 ± 8 0.590a
Glycosylated haemoglobin (% [mmol/mol]) 7.10 ± 3.20 [54.20 ± 11.95] 7.90 ± 3.40 [62.89 ± 13.81] 0.160a
Systolic blood pressure (mm/Hg) 127.3 ± 10.6 132.9 ± 11.7 0.275a
Diastolic blood pressure (mm/Hg) 78.0 ± 10.6 76.8 ± 6.2 0.751a
Triglycerides (mmol/L) 0.94 ± 0.58 1.04 ± 0.62 0.726a
Cholesterol (mmol/L) 4.25 ± 0.88 4.09 ± 0.45 0.637a
Omega‑3 index (%) 4.93 ± 0.94 4.31 ± 1.15 0.206a
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Table 2 6-months high-dose-bolus n-3PUFA supplementation on  vascular health, glycemic control, and  metabolic 
parameters in T1D
Outcome Pretreatment 3 months 6 months 9 months P value
n‑3PUFA Placebo n‑3PUFA Placebo n‑3PUFA Placebo n‑3PUFA Placebo
Vascular health
 Vascular cell 
adhesion 
molecule‑1 
(ng/mL)
823.83 ± 593.23 752.4 ± 631.97 865.58 ± 659.42 730.00 ± 610.72 848.12 ± 608.67 708.14 ± 691.22 843.17 ± 603.50 788.55 ± 603.53 0.833
 Intercellular 
adhesion 
molecule‑1 
(ng/mL)
1225 ± 817 865 ± 205 1231 ± 845 945 ± 422 1221 ± 807 800 ± 170 1182 ± 796 831 ± 197 0.491
 Vascular 
endothelial 
growth 
factor (pg/
mL)
87.97 ± 45.03 75.06 ± 24.43 90.55 ± 47.56 87.54 ± 57.44 92.47 ± 52.52 63.74 ± 17.20 83.21 ± 45.49 71.18 ± 18.98 0.271
 E‑Selectin 
(ng/mL)
41.14 ± 21.79 45.45 ± 13.35 41.40 ± 21.93 44.64 ± 16.78 39.31 ± 20.74 41.53 ± 10.35 36.64 ± 18.76 44.54 ± 15.32 0.598
 P‑Selectin 
(ng/mL)
32.81 ± 12.51 37.73 ± 11.48 33.61 ± 14.05 37.70 ± 9.84 31.25 ± 11.57 35.17 ± 8.14 33.66 ± 14.06 35.29 ± 8.05 0.842
 Pentraxin‑3 
(ng/mL)
3.80 ± 3.62 2.31 ± 1.25 3.89 ± 3.80 2.94 ± 2.88 3.77 ± 3.60 2.07 ± 0.98 3.71 ± 3.50 2.33 ± 1.31 0.529
 Tumor necro‑
sis factor 
alpha (pg/
mL)
56.48 ± 41.77 59.25 ± 26.25 57.19 ± 43.15 61.57 ± 34.65 56.48 ± 41.76 55.67 ± 24.26 53.86 ± 38.26 57.80 ± 27.17 0.678
 Far wall 
carotid 
intima‑
media 
thickness 
(mm)
0.61 ± 0.12 0.64 ± 0.09 0.59 ± 0.11 0.64 ± 0.09 0.60 ± 0.10 0.64 ± 0.09 0.60 ± 0.11 0.64 ± 0.09 0.216
 Flow medi‑
ated dila‑
tion (%)
6.99 ± 1.45 7.42 ± 1.29 7.03 ± 1.48 7.24 ± 1.58 6.84 ± 1.61 7.25 ± 1.59 6.82 ± 1.36 7.26 ± 1.53 0.332
 Systolic blood 
pressure 
(mm/Hg)
127 ± 11 133 ± 12 121 ± 11 127 ± 10 126 ± 6 123 ± 9 124 ± 12 124 ± 9 0.248
 Diastolic 
blood pres‑
sure (mm/
Hg)
78 ± 10 77 ± 6 69. ± 6 74 ± 7 69 ± 6 72 ± 7 68 ± 7 70 ± 5 0.466
Glycemic control
 Glycosylated 
haemoglo‑
bin (mmol/
mol)
54.20 ± 11.95 62.89 ± 13.81 57.60 ± 11.70 61.22 ± 12.18 57.70 ± 13.63 64.33 ± 14.40 58.10 ± 12.24 62.00 ± 11.95 0.404
 Fasting 
plasma 
glucose 
(mmol/L)a
11.51 ± 4.16 10.44 ± 4.02 12.40 ± 5.78 9.55 ± 4.93 12.25 ± 4.76 10.99 ± 4.28 13.12 ± 4.72 10.44 ± 3.11 0.798
 PPGR 
(mmol/L/
min)c
5423 ± 1223 5687 ± 3213 5979 ± 2042 5144 ± 2294 6030 ± 1856 5169 ± 2435 6883 ± 1975 5324 ± 2253 0.135
Metabolic parameters
 Triglycerides 
(mmol/L)a
1.02 ± 0.65 1.11 ± 0.63 0.98 ± 0.41 1.07 ± 0.55 0.92 ± 0.54 1.15 ± 0.49 1.06 ± 0.56 1.20 ± 0.69 0.858
 PPTR 
(mmol/L/
min)c
610.08 ± 331.62 662 ± 401 578 ± 209 600 ± 227 567 ± 243 676 ± 398 641 ± 173 669 ± 326 0.792
 Cholesterol 
(mmol/L)b
4.23 ± 0.91 4.11 ± 0.47 4.22 ± 0.45 4.16 ± 0.59 5.01 ± 1.46 3.96 ± 0.71 4.80 ± 1.60 4.33 ± 1.44 0.432
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majority of our subjects presented with relatively good 
glycaemic control (~ 7.1% [~ 54 mmol/mol]) with triglyc-
eride levels < 1.0 mmol/L at study entry. Thus, we cannot 
exclude the possibility that n-3PUFA supplementation 
over a longer duration or in less well-controlled subjects 
(± comorbidities) may have nongenomic effects on gly-
caemic control, metabolic health or vascular health, that 
were not detectable in our cohort or by our study design. 
Whilst we administered n-3PUFA at a dose above the 
2 g/day minimum suggested necessary to elicit beneficial 
cardiovascular effects [52], the current study focused on 
the additive effects of n-3PUFA to habitual dietary hab-
its given the known poor adherence to chronic dietary 
changes [53]. However, research suggests that n-3PUFA 
supplementation alone is insufficient and needs to 
replace saturated fatty acid intake in order to modify 
CVD risk [54]. While increased n-3PUFA intake may 
reduce the risk of developing T1D [55], the current study 
questions the therapeutic utility and disease modifying 
potential of n-3PUFA in adults with T1D.
Strengths and limitations
Although the strengths of this study include its double-
blind randomised placebo-controlled design; long sup-
plementation duration and daily high dose of n-3PUFA; 
assessment of legacy effects and follow-up after wash-
out; objective assessment of compliance via erythrocyte 
gas chromatography; the inclusion of a broad and com-
prehensive assessment of outcomes using gold-standard 
measures; and control of pretreatment fatty acid com-
position and subject characteristics it is not without 
limitations. Firstly, the broad selection of subjects with 
different treatment regimens, duration of disease, and sex 
may have caused heterogeneity in the study sample and 
may have masked a positive effect. However, controlling 
for these potentially confounding factors in our statisti-
cal analysis did not change the outcome of study findings 
and increases generalizability. The obtained sample size 
was relatively small and the number of subjects lost to 
follow up was proportionately high. However, our sam-
ple size was deemed sufficient to yield adequate statistical 
power across outcomes, and is comparable to previously 
published RCTs assessing the effectiveness of n-3PUFA 
supplementation in adults with T1D [14, 18].
Conclusions
This study indicates that daily high-dose-bolus n-3PUFA 
supplementation for 6-months does not improve vascu-
lar health, glucose homeostasis, or metabolic parameters 
in well controlled subjects with T1D without existing 
microvascular complications. Despite the lack of evi-
dence to support clinical benefit, n-3PUFA supplemen-
tation is common in people living with T1D. However, 
the findings from this preliminary RCT do not support 
the use of therapeutic n-3PUFA supplementation in 
the treatment and management of T1D and its associ-
ated complications. Future research is needed to assess 
the effectiveness of other potential adjunct therapies 
that may act to modify the markedly elevated CVD risk 
amongst adults with T1D.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1293 3‑020‑01094 ‑5.
Additional file 1: Figure S1. Schematic representation of study design. 
n‑3PUFA, omega‑3 polyunsaturated fatty acid; = blood sampling; 
ultrasound imaging. Laboratory visits were scheduled at week 0, 12, 24, 
and 36. Table S1. Macronutrient composition of mixed‑meal tolerance 
tests. Table S2. Erythrocyte fatty acid profiles in response to n‑3PUFA 
supplementation or placebo in adults with type 1 diabetes. Mean ± 
Table 2 (continued)
Outcome Pretreatment 3 months 6 months 9 months P value
n‑3PUFA Placebo n‑3PUFA Placebo n‑3PUFA Placebo n‑3PUFA Placebo
 Non‑
esterified 
fatty acids 
(mmol/L)b
0.37 ± 0.18 0.57 ± 0.36 0.48 ± 0.37 0.39 ± 0.16 0.38 ± 0.40 0.54 ± 0.32 0.52 ± 0.36 0.55 ± 0.29 0.254
Anthropometry
 Body weight 
(kg)
82.56 ± 15.34 80.22 ± 19.07 82.56 ± 14.30 80.83 ± 18.61 82.15 ± 15.47 80.96 ± 18.85 82.53 ± 14.96 80.56 ± 17.87 0.669
 Body mass 
index (kg/
m2)
25.13 ± 3.43 28.14 ± 6.38 25.20 ± 3.29 27.13 ± 4.78 25.10 ± 3.71 27.40 ± 5.10 25.19 ± 3.40 27.25 ± 4.44 0.552
 Body Fat (%) 19.43 ± 6.86 26.47 ± 15.47 19.65 ± 6.73 25.09 ± 10.85 19.48 ± 7.49 25.83 ± 11.68 19.36 ± 7.50 24.68 ± 11.17 0.739
n = 10 in both groups unless stated otherwise. Values are presented as mean ± SD. Follow-up at 9-months was after 3-months washout. n-3PUFA, omega-3 
polyunsaturated fatty acid; a, n = (n-3PUFA: 9; PLA: 9); b, n = (n-3PUFA: 6; PLA: 8); c, n = (n-3PUFA: 6; PLA: 7); PPGR, postprandial glucose response; PPTR, postprandial 
triglyceride response. Postprandial responses presented as sum of the area under the curve (0–8 h) following two consecutive mixed-meal tolerance tests
Page 9 of 10O’Mahoney et al. Cardiovasc Diabetol          (2020) 19:127  
SD. n=10 in each group. *, p<0.05; **, p<0.01; ***, p<0.001. n‑3PUFA, 
omega‑3 polyunsaturated fatty acids. All values are expressed as a 
percentage of total identified fatty acids after response factor correction. 
Table S3. Adjusted analysis for the effects of n‑3PUFA supplementation 
on multiple health outcomes in adults with type 1 diabetes. Table S4. Pre‑
treatment demographic and clinical characteristics of intention‑to‑treat 
cohort. Table S5. Effect of omega‑3 polyunsaturated fatty acids (n3PUFA) 
or placebo on cardiovascular and metabolic biomarkers, glycaemic 
parameters, measures of anthropometry, and vascular structure and func‑
tion as per intention‑to‑treat analysis.
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